180 related articles for article (PubMed ID: 24938872)
1. MEK inhibitor effective against proliferation in breast cancer cell.
Zhou Y; Hu HY; Meng W; Jiang L; Zhang X; Sha JJ; Lu Z; Yao Y
Tumour Biol; 2014 Sep; 35(9):9269-79. PubMed ID: 24938872
[TBL] [Abstract][Full Text] [Related]
2. Selumetinib suppresses cell proliferation, migration and trigger apoptosis, G1 arrest in triple-negative breast cancer cells.
Zhou Y; Lin S; Tseng KF; Han K; Wang Y; Gan ZH; Min DL; Hu HY
BMC Cancer; 2016 Oct; 16(1):818. PubMed ID: 27769200
[TBL] [Abstract][Full Text] [Related]
3. MiR-92a mediates AZD6244 induced apoptosis and G1-phase arrest of lymphoma cells by targeting Bim.
Lv XB; Zhang X; Deng L; Jiang L; Meng W; Lu Z; Wang X
Cell Biol Int; 2014 Apr; 38(4):435-43. PubMed ID: 24375836
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA 9-3p targets β1 integrin to sensitize claudin-low breast cancer cells to MEK inhibition.
Zawistowski JS; Nakamura K; Parker JS; Granger DA; Golitz BT; Johnson GL
Mol Cell Biol; 2013 Jun; 33(11):2260-74. PubMed ID: 23530058
[TBL] [Abstract][Full Text] [Related]
5. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.
Gopal YN; Deng W; Woodman SE; Komurov K; Ram P; Smith PD; Davies MA
Cancer Res; 2010 Nov; 70(21):8736-47. PubMed ID: 20959481
[TBL] [Abstract][Full Text] [Related]
6. Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines.
Garon EB; Finn RS; Hosmer W; Dering J; Ginther C; Adhami S; Kamranpour N; Pitts S; Desai A; Elashoff D; French T; Smith P; Slamon DJ
Mol Cancer Ther; 2010 Jul; 9(7):1985-94. PubMed ID: 20587667
[TBL] [Abstract][Full Text] [Related]
7. Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.
Tentler JJ; Nallapareddy S; Tan AC; Spreafico A; Pitts TM; Morelli MP; Selby HM; Kachaeva MI; Flanigan SA; Kulikowski GN; Leong S; Arcaroli JJ; Messersmith WA; Eckhardt SG
Mol Cancer Ther; 2010 Dec; 9(12):3351-62. PubMed ID: 20923857
[TBL] [Abstract][Full Text] [Related]
8. Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways.
Kandil E; Tsumagari K; Ma J; Abd Elmageed ZY; Li X; Slakey D; Mondal D; Abdel-Mageed AB
J Surg Res; 2013 Oct; 184(2):898-906. PubMed ID: 23602735
[TBL] [Abstract][Full Text] [Related]
9. STAT3 mediates resistance to MEK inhibitor through microRNA miR-17.
Dai B; Meng J; Peyton M; Girard L; Bornmann WG; Ji L; Minna JD; Fang B; Roth JA
Cancer Res; 2011 May; 71(10):3658-68. PubMed ID: 21444672
[TBL] [Abstract][Full Text] [Related]
10. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Liu Y; Chen X; Luo Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
[TBL] [Abstract][Full Text] [Related]
11. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.
Meng J; Dai B; Fang B; Bekele BN; Bornmann WG; Sun D; Peng Z; Herbst RS; Papadimitrakopoulou V; Minna JD; Peyton M; Roth JA
PLoS One; 2010 Nov; 5(11):e14124. PubMed ID: 21124782
[TBL] [Abstract][Full Text] [Related]
12. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma.
Huynh H; Soo KC; Chow PK; Tran E
Mol Cancer Ther; 2007 Jan; 6(1):138-46. PubMed ID: 17237274
[TBL] [Abstract][Full Text] [Related]
13. miR-19 targeting of PTEN mediates butyl benzyl phthalate-induced proliferation in both ER(+) and ER(-) breast cancer cells.
Wu J; Jiang Y; Cao W; Li X; Xie C; Geng S; Zhu M; Liang Z; Zhu J; Zhu W; Wu R; Ma X; Huang C; Yang X; Wang S; Zhong C
Toxicol Lett; 2018 Oct; 295():124-133. PubMed ID: 29864457
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
Qu Y; Wu X; Yin Y; Yang Y; Ma D; Li H
J Exp Clin Cancer Res; 2014 Jun; 33(1):52. PubMed ID: 24939055
[TBL] [Abstract][Full Text] [Related]
15. Silencing of human phosphatidylethanolamine-binding protein 4 sensitizes breast cancer cells to tumor necrosis factor-alpha-induced apoptosis and cell growth arrest.
Wang X; Li N; Li H; Liu B; Qiu J; Chen T; Cao X
Clin Cancer Res; 2005 Oct; 11(20):7545-53. PubMed ID: 16243830
[TBL] [Abstract][Full Text] [Related]
16. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.
Bartholomeusz C; Oishi T; Saso H; Akar U; Liu P; Kondo K; Kazansky A; Krishnamurthy S; Lee J; Esteva FJ; Kigawa J; Ueno NT
Mol Cancer Ther; 2012 Feb; 11(2):360-9. PubMed ID: 22144664
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of miR-660-5p expression suppresses tumor development and metastasis in human breast cancer.
Shen Y; Ye YF; Ruan LW; Bao L; Wu MW; Zhou Y
Genet Mol Res; 2017 Feb; 16(1):. PubMed ID: 28252173
[TBL] [Abstract][Full Text] [Related]
18. Dual treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line.
Ayub A; Yip WK; Seow HF
Biomed Pharmacother; 2015 Oct; 75():40-50. PubMed ID: 26463630
[TBL] [Abstract][Full Text] [Related]
19. The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma.
Bhalla S; Evens AM; Dai B; Prachand S; Gordon LI; Gartenhaus RB
Blood; 2011 Jul; 118(4):1052-61. PubMed ID: 21628402
[TBL] [Abstract][Full Text] [Related]
20. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.
Hu C; Huang L; Gest C; Xi X; Janin A; Soria C; Li H; Lu H
J Hematol Oncol; 2012 Jul; 5():16. PubMed ID: 22534171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
